Overview

Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is an open Label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in healthy adult human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Anticonvulsants
Lamotrigine